person · Reporting owner

ENGELSEN STEINAR J

Disclosed activity across 2 companies

Tapewire entity: 133957
SEC CIK: 0001218860

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INSMED IncINSM · Entity 3174	Director	November 01, 2021	November 03, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSMED Inc

Report date November 01, 2021 · Filed November 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	320,802	Reported balance After 2021-11-01 transaction · row 1 1 source row Row 1 · 2021-11-01 · Purchase · Acquired 14,235 · Balance 320,802 F1: This is the weighted average sales price representing the shares purchased at prices ranging from $30.05 to $30.25 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares purchased at each price within the price range upon request.

Filing footnotes · ownership attribution and instrument terms

F1: This is the weighted average sales price representing the shares purchased at prices ranging from $30.05 to $30.25 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares purchased at each price within the price range upon request.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SOLENO THERAPEUTICS INC

Report date February 05, 2018 · Filed February 08, 2018

Section 16 reporting ended · disclosed 2018-02-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	41,831	Reported balance After 2018-02-05 transaction · row 1 1 source row Row 1 · 2018-02-05 · Grant · Acquired 8,109 · Balance 41,831 F3: Resigned from the Board of Directors effective December 31, 2017. Fees incurred for 2017 Board and committee services. F1: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263.

Filing footnotes · ownership attribution and instrument terms

F1: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.

F2: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263.

F3: Resigned from the Board of Directors effective December 31, 2017. Fees incurred for 2017 Board and committee services.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 01, 2021 Filed Nov 3, 2021 20:26 UTC	INSMED Inc INSM · Entity 3174	PurchaseCommon Stock	14,235	$30.14	$429,042.90	Disclosure SEC source: 0001140361-21-036421 · form4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,802 F1 · price: This is the weighted average sales price representing the shares purchased at prices ranging from $30.05 to $30.25 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares purchased at each price within the price range upon request. Read SEC document
May 12, 2021 Filed May 14, 2021 20:43 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	7,558	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-21-017430 · form4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,567 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2021 for no consideration. Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:09 UTC	INSMED Inc INSM · Entity 3174	PurchaseCommon Stock	2,710	$36.90	$99,999.00	Disclosure SEC source: 0001140361-21-007636 · form4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,009 Read SEC document
May 12, 2020 Filed May 15, 2020 00:59 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	8,097	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-061855 · a4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,299 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2020 for no consideration. Read SEC document
May 15, 2019 Filed May 16, 2019 21:17 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,899	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-19-000076 · edgar.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,202 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the vesting date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit granted on May 15, 2019, and represents a contingent right to receive one share of Common Stock. Read SEC document
November 01, 2018 Filed Nov 2, 2018 20:07 UTC	INSMED Inc INSM · Entity 3174	PurchaseCommon Stock	16,085	$15.79	$253,993.41	Disclosure SEC source: 0001127430-18-000068 · edgar.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,303 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.60 to $15.93. The price reported above reflect the weighted average price. The number of shares sold at each separate price will be made available to the SEC staff, the issuer or a security holder of the issuer upon request. Read SEC document
May 15, 2018 Filed May 17, 2018 20:13 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,066	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-18-000039 · edgar.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,218 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock. Read SEC document
February 05, 2018 Filed Feb 8, 2018 00:38 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	8,109	$1.73	$13,998.57	Disclosure SEC source: 0000899243-18-003150 · doc4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,831 F3 · date: Resigned from the Board of Directors effective December 31, 2017. Fees incurred for 2017 Board and committee services. F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263. Read SEC document
October 02, 2017 Filed Oct 4, 2017 22:01 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	26,923	$0.52	$13,999.96	Disclosure SEC source: 0000899243-17-023575 · doc4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,612 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or $0.52. Read SEC document
July 06, 2017 Filed Jul 18, 2017 00:56 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	22,951	$0.61	$14,000.11	Disclosure SEC source: 0000899243-17-018365 · doc4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,689 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61. Read SEC document
May 17, 2017 Filed May 19, 2017 20:29 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,702	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-17-000042 · edgar.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,152 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was received as a grant on May 17, 2017, and represents a contingent right to receive one share of Common Stock. Read SEC document
May 08, 2017 Filed May 9, 2017 20:39 UTC	SOLENO THERAPEUTICS INC CAPN · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	45,139	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0000899243-17-012485 · doc4.xml · derivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,139 Underlying: Common Stock · 45,139 shares Expires 2027-05-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is May 8, 2017) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document
April 07, 2017 Filed Apr 14, 2017 00:55 UTC	SOLENO THERAPEUTICS INC CAPN · Entity 46432	GrantCommon Stock	22,222	$0.63	$13,999.86	Disclosure SEC source: 0000899243-17-010270 · doc4.xml · nonDerivative · entry 2 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,738 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F3 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63. Read SEC document
January 23, 2017 Filed Apr 14, 2017 00:55 UTC	SOLENO THERAPEUTICS INC CAPN · Entity 46432	GrantCommon Stock	15,556	$0.90	$14,000.40	Disclosure SEC source: 0000899243-17-010270 · doc4.xml · nonDerivative · entry 1 ENGELSEN STEINAR J · CIK 0001218860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,516 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on January 23, 2017, or $0.90. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.